Callco

Calico Life Sciences is an Alphabet-backed biotechnology company dedicated to understanding the biology of aging and developing interventions to extend human healthspan. Founded in 2013 by Arthur Levinson and Bill Maris, the company leverages advanced technologies, systems biology, and machine learning to identify novel targets for age-related diseases. Calico operates through a significant long-term R&D collaboration with AbbVie, which has yielded a pipeline of clinical-stage candidates in oncology and neurodegeneration. Its lead programs include eIF2B activators for neurodegenerative conditions and PTPN2 inhibitors for immuno-oncology. The company is known for its long-term research horizon and its mission to enable people to lead longer and healthier lives.